Tradestie Institutional Equity Comparison Engine

CNTX vs SGMT โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

SGMT Overall Edge

SGMT Captures Institutional Edge (3โ€“0 Pillars ยท 4โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Sagimet Biosciences Inc. Series A Common Stock (SGMT) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, CNTX trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus SGMT at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, CNTX sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against SGMT sits in CONSOLIDATION (82nd %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
CNTX N/M vs SGMT N/M Fwd P/E
Growth & Margin Winner SGMT
Op Margin 0.0% vs 0.0% ยท YoY +0.0% vs +0.0%
Momentum & Technical Winner SGMT
1Y -86.3% vs +15.7% ยท 52W Pos 0% vs 66%
Options & Structure Winner SGMT
UNCLASSIFIED (N/A IV) vs CONSOLIDATION (82nd %ile IV)
CNTX NASDAQ
Context Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$0.16
-5.1% 1D
Market Cap $15.5M
1M Return -32.09%
1Y Return -86.32%
Forward P/E N/M
Unified AI Score
46.6 / 100 HOLD
Tech 33.0 Fund 58.0 Flow 50.0 Mom 68.9
SGMT NASDAQ
Sagimet Biosciences Inc. Series A Common Stock
Pharmaceutical Preparations
$9.08
-5.61% 1D
Market Cap $692.0M
1M Return -8.74%
1Y Return +15.67%
Forward P/E N/M
Unified AI Score
44.6 / 100 HOLD
Tech 22.0 Fund 48.0 Flow 70.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: CNTX -86.32% SGMT +15.67% Spread: +101.99 pp (SGMT Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
CNTX TTM Op. Margin: 0.0% SGMT TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CNTX vs SGMT. Trailing 12-month operating profitability (CNTX 0.0% vs SGMT 0.0%) and valuation multiples (CNTX N/M vs SGMT N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: CNTX (1) vs SGMT (4)
Institutional Metric CNTX SGMT Criterion Row Winner
Market Capitalization Scale $15.5M $692.0M Larger Scale SGMT
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% +0.0% Higher Growth Tie
Operating Margin (TTM) Profitability 0.0% 0.0% Higher Margin Tie
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -84.3% -29.5% Higher ROE SGMT
52-Week Range Position Momentum 0% ($0โ€“$4) 66% ($4โ€“$11) Stronger Trend SGMT
Beta / 30D Volatility Risk Regime 0.82ฮฒ ยท 98% Vol 2.04ฮฒ ยท 80% Vol Lower Realized Risk SGMT
Unified Institutional Score Composite Signal 46.6 / 100 (HOLD) 44.6 / 100 (HOLD) Higher Composite CNTX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full CNTX vs SGMT Buy Guide
CNTX UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live CNTX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
SGMT CONSOLIDATION
144d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 82nd %ile
IV Regime Extreme (>80th %ile)
Live SGMT Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither CNTX nor SGMT registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.